|Trade names||Celebrex, Onsenal, Elyxyb, others|
|Drug class||NSAID (COX-2 inhibitor)|
|Main uses||Pain, inflammation|
|Side effects||Abdominal pain, nausea, diarrhea|
|Defined daily dose||200 mg|
|Protein binding||97% (mainly to serum albumin)|
|Metabolism||Liver (mainly CYP2C9)|
|Elimination half-life||7.8 hours; 11 hours (mild hepatic impairment); 13 hours (moderate-severe hepatic impairment)|
|Excretion||Faeces (57%), urine (27%)|
|Chemical and physical data|
|Molar mass||381.373 g·mol−1|
|3D model (JSmol)|
Celecoxib, sold under the brand name Celebrex among others, is a COX-2 inhibitor and nonsteroidal anti-inflammatory drug (NSAID). It is used to treat the pain and inflammation in osteoarthritis, acute pain in adults, rheumatoid arthritis, ankylosing spondylitis, painful menstruation, and juvenile rheumatoid arthritis. It may also be used to decrease the risk of colorectal adenomas in people with familial adenomatous polyposis. It is taken by mouth. Benefits are typically seen within an hour.
Common side effects include abdominal pain, nausea, and diarrhea. Serious side effects may include heart attacks, strokes, gastrointestinal perforation, gastrointestinal bleeding, kidney failure, and anaphylaxis. Use is not recommended in people at high risk for heart disease. The risks are similar to other NSAIDs, such as ibuprofen and naproxen. Use in the later part of pregnancy or during breastfeeding is not recommended.
Celecoxib was patented in 1993 and came into medical use in 1999. It is available as a generic medication. A month supply in the United Kingdom costs the NHS less than £2 as of 2019. In the United States, the wholesale cost of this amount is about $US12.90. In 2011, it was one of Pfizer's best-selling medications, with $2.5 billion in sales. In 2017, it was the 106th most commonly prescribed medication in the United States, with more than seven million prescriptions.
Celecoxib is indicated for the treatment of osteoarthritis, rheumatoid arthritis, acute pain, musculoskeletal pain, painful menstruation, ankylosing spondylitis, juvenile rheumatoid arthritis, and to reduce the number of colon and rectal polyps in people with familial adenomatous polyposis. It may be used in children with juvenile rheumatoid arthritis who are older than two years of age and weigh more than 10 kg (22 lb).
For postoperative pain, it is more or less equal to ibuprofen. For pain relief, it is similar to paracetamol (acetaminophen), which is the first line treatment for osteoarthritis.
Evidence of effects are not clear as a number of studies done by the manufacturer have not been released for independent analysis.
Tentative evidence supports its use in treating a number of psychiatric disorders, including major depression, bipolar disorder, and schizophrenia.
Familial adenomatous polyposis
It has been used to reduce colon and rectal polyps in people with familial adenomatous polyposis, but it is not known if it decreases rates of cancer, so it is not a good choice for this reason.
The defined daily dose is 200 mg by mouth.
- Cardiovascular events: NSAIDs are associated with an increased risk of serious (and potentially fatal) adverse cardiovascular thrombotic events, including myocardial infarction and stroke. Risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease. Individual cardiovascular risk profiles should be evaluated prior to prescribing. New-onset hypertension or exacerbation of hypertension may occur (NSAIDs may impair response to thiazide or loop diuretics), and may contribute to cardiovascular events; monitor blood pressure and use with caution in patients with hypertension. May cause sodium and fluid retention, use with caution in patients with edema or heart failure. Long-term cardiovascular risk in children has not been evaluated. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; alternative therapies should be considered for patients at high risk. The increased risk is about 37%.
- Gastrointestinal events: NSAIDs may increase risk of serious gastrointestinal (GI) ulceration, bleeding, and perforation (may be fatal). These events may occur at any time during therapy and without warning. Use caution with a history of GI disease (bleeding or ulcers), concurrent therapy with aspirin, anticoagulants and/or corticosteroids, smoking, use of alcohol, the elderly or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; alternate therapies should be considered for patients at high risk. When used concomitantly with ≤325 mg of aspirin, a substantial increase in the risk of gastrointestinal complications (e.g., ulcer) occurs; concomitant gastroprotective therapy (e.g., proton pump inhibitors) is recommended. The increased risk is about 81%.
- Hematologic effects: Anemia may occur; monitor hemoglobin or hematocrit in people on long-term treatment. Celecoxib does not usually affect prothrombin time, partial thromboplastin time or platelet counts; it does not inhibit platelet aggregation at approved doses.
People with prior history of ulcer disease or GI bleeding require special precaution. Moderate to severe liver impairment or GI toxicity can occur with or without warning symptoms in people treated with NSAIDs.
In October 2020, the U.S. Food and Drug Administration (FDA) required the drug label to be updated for all nonsteroidal anti-inflammatory medications to describe the risk of kidney problems in unborn babies that result in low amniotic fluid. They recommend avoiding NSAIDs in pregnant women at 20 weeks or later in pregnancy.
Celecoxib contains a sulfonamide moiety and may cause allergic reactions in those allergic to other sulfonamide-containing drugs. This is in addition to the contraindication in people with severe allergies to other NSAIDs. However, it has a low (reportedly 4%) chance of inducing cutaneous reactions among persons who have a history of such reactions to aspirin or nonselective NSAIDs. NSAIDs may cause serious skin adverse events, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis; events may occur without warning and in patients without prior known sulfa allergy. Use should be discontinued at first sign of rash (or any other hypersensitivity).
Heart attack and stroke
A 2013 meta-analysis of hundreds of clinical trials found that coxibs (the class of drugs that includes celecoxib) increase the risk of major cardiovascular problems by about 37% over placebo. In 2016, a randomized trial provided strong evidence that treatment with celecoxib is not more likely to result in poor cardiovascular outcomes than treatment with naproxen or ibuprofen. As a result, in 2018 an FDA advisory panel concluded that celecoxib poses no greater risk for causing heart attacks and strokes than the commonly-used NSAIDs ibuprofen or naproxen and recommended that the FDA consider changing its advice to physicians regarding celecoxib's safety.
The COX-2 inhibitor rofecoxib (Vioxx) was removed from the market in 2004 due to its risk. Like all NSAIDs on the US market, celecoxib carries an FDA-mandated "black box warning" for cardiovascular and gastrointestinal risk. In February 2007, the American Heart Association warned that with respect to "patients with a prior history of or at high risk for cardiovascular disease... use of COX-2 inhibitors for pain relief should be limited to patients for whom there are no appropriate alternatives, and then, only in the lowest dose and for the shortest duration necessary."
In 2005, a study published in the Annals of Internal Medicine found that cardiovascular effects of COX-2 inhibitors differ, depending on the drug. Other COX-2-selective inhibitors, such as rofecoxib, have significantly higher myocardial infarction rates than celecoxib. In April 2005, after an extensive review of data, the FDA concluded it was likely "that there is a 'class effect' for increased CV risk for all NSAIDs". In a 2006 meta-analysis of randomized control studies, the cerebrovascular events associated with COX-2 inhibitors were examined, but no significant risks were found when compared to nonselective NSAIDs or placebos.
Celecoxib is predominantly metabolized by cytochrome P450 2C9. Caution must be exercised with concomitant use of 2C9 inhibitors, such as fluconazole, which can greatly elevate celecoxib serum levels. If used concomitantly with lithium, celecoxib increases lithium plasma levels. If used concomitantly with warfarin, celecoxib may result in increased risk of bleeding complications. The risk of bleeding and gastric ulcers also increase further when SSRIs are used in combination with celecoxib. The drug may increase the risk of kidney failure with angiotensin-converting enzyme-inhibitors, such as lisinopril, and diuretics, such as hydrochlorothiazide.
In the US FDA's pregnancy categories, the drug is category C prior to 30 weeks gestation, and category D starting at 30 weeks gestation.
Mechanism of action
A highly selective reversible inhibitor of the COX-2 isoform of cyclooxygenase, celecoxib inhibits the transformation of arachidonic acid to prostaglandin precursors. Therefore, it has analgesic and anti-inflammatory properties. Nonselective NSAIDs (such as aspirin, naproxen, and ibuprofen) inhibit both COX-1 and COX-2. Inhibition of COX-1 (which celecoxib does not inhibit at therapeutic concentrations) inhibits the production of prostaglandins and the production of thromboxane A2, a platelet activator. COX-1 is traditionally defined as a constitutively expressed "housekeeping" enzyme and plays a role in the protection of the gastrointestinal mucosa, kidney hemodynamics, and platelet thrombogenesis. COX-2, on the contrary, is extensively expressed in cells involved in inflammation and is upregulated by bacterial lipopolysaccharides, cytokines, growth factors, and tumor promoters. Celecoxib is approximately 10-20 times more selective for COX-2 inhibition over COX-1. It binds with its polar sulfonamide side chain to a hydrophilic side pocket region close to the active COX-2 binding site. In theory, this selectivity allows celecoxib and other COX-2 inhibitors to reduce inflammation (and pain) while minimizing gastrointestinal adverse drug reactions (e.g. stomach ulcers) that are common with nonselective NSAIDs.
For its use in reducing colon polyps, celecoxib affects genes and pathways involved in inflammation and malignant transformation in tumors, but not normal tissues.
Celecoxib binds to Cadherin-11 (which may explain the reduction in cancer progression).
The Searle research group found the two appropriately substituted aromatic rings must reside on adjacent positions about the central ring for adequate COX-2 inhibition. Various modifications can be made to the 1,5-diarylpyrazole moiety to deduce the structure-activity relationship of celecoxib. A para-sulfamoylphenyl at position 1 of the pyrazole was found to have a higher potency for COX-2 selective inhibition than a para-methoxyphenyl (see structures 1 and 2, below). In addition, a 4-(methylsulfonyl)phenyl or 4-sulfamoylphenyl is known to be necessary for COX-2 inhibition. For instance, replacing either of these entities with a –SO2NHCH3 substituent diminishes COX-2 inhibitory activity as noted with a very high inhibitory concentration-50 (see structures 3 – 5). At the 3-position of the pyrazole, a trifluoromethyl or difluoromethyl provides superior selectivity and potency compared to a fluoromethyl or methyl substitution (see structures 6 – 9).
Celecoxib is compound 22; the 4-sulfamoylphenyl on the 1-pyrazol substituent is required for COX-2 inhibition and the 4-methyl on the 5-pyrazol system has low steric hindrance to maximize potency, while the 3-trifluoromethyl group provides superior selectivity and potency. To explain the selectivity of celecoxib, it is necessary to analyze the free energy of binding difference between the drug molecule and COX-1 compared to COX-2 enzymes. The structural modifications highlight the importance of binding to residue 523 in the side binding pocket of the cyclooxygenase enzyme, which is an isoleucine in COX-1 and a valine in COX-2. This mutation appears to contribute to COX-2 selectivity by creating steric hindrance between the sulfonamide oxygen and the methyl group of Ile523 that effectively destabilizes the celecoxib-COX-1 complex. Thus, it is reasonable to expect COX-2-selective inhibitors to be more bulky than nonselective NSAIDs.
It was initially marketed by Pfizer for arthritis. Celecoxib and other COX-2 selective inhibitors, valdecoxib, parecoxib, and mavacoxib, were discovered by a team at the Searle division of Monsanto led by John Talley.
Two lawsuits arose over discovery of celecoxib. Daniel L. Simmons of Brigham Young University (BYU) discovered the COX-2 enzyme in 1988, and in 1991, BYU entered into a collaboration with Monsanto to develop drugs to inhibit it. Monsanto's pharmaceutical division was later purchased by Pfizer, and in 2006, BYU sued Pfizer for breach of contract, claiming Pfizer did not properly pay contractual royalties back to BYU. A settlement was reached in April 2012, in which Pfizer agreed to pay $450 million. Other important discoveries in COX-2 were made at University of Rochester, which patented the discoveries. When the patent issued, the university sued Searle (later Pfizer) in a case called, University of Rochester v. G.D. Searle & Co., 358 F.3d 916 (Fed. Cir. 2004). The court ruled in favor of Searle in 2004, holding in essence that the university had claimed a method requiring, yet provided no written description of, a compound that could inhibit COX-2 and therefore the patent was invalid.
According to the National Academy of Sciences, Philip Needleman, who was vice president of Monsanto in 1989 and president of Searle in 1993 oversaw research into COX-2 that led to the development of the anti-inflammatory drug celecoxib (Celebrex). He became senior executive vice president and chief scientist of Pharmacia from 2000 to 2003. Celecoxib was discovered and developed by G. D. Searle & Company and was approved by the FDA on December 31, 1998. It was co-promoted by Monsanto Company (parent company of Searle) and Pfizer under the brand name Celebrex. Monsanto merged with Pharmacia, from which the Medical Research Division was acquired by Pfizer, giving Pfizer ownership of Celebrex. The drug was at the core of a major patent dispute that was resolved in Searle's favor (later Pfizer) in 2004. In University of Rochester v. G.D. Searle & Co., 358 F.3d 916 (Fed. Cir. 2004), the University of Rochester claimed that United States Pat. No. 6,048,850 (which claimed a method of inhibiting COX-2 in humans using a compound, without actually disclosing what that compound might be) covered drugs such as celecoxib. The court ruled in favor of Searle, holding in essence that the University had claimed a method requiring, yet provided no written description of, a compound that could inhibit COX-2 and therefore the patent was invalid.
After the withdrawal of rofecoxib from the market in September 2004, celecoxib enjoyed a robust increase in sales. However, the results of the APC trial in December of that year raised concerns that Celebrex might carry risks similar to those of rofecoxib, and Pfizer announced a moratorium on direct-to-consumer advertising of Celebrex soon afterwards. Sales reached $2 billion in 2006. Prior to its availability in generic form, it was one of Pfizer's "best-selling drugs, amounting to more than $2.5 billion in sales [by 2012], and was prescribed to 2.4 million" people in 2011. By 2012, 33 million Americans had taken celecoxib.
Pfizer resumed advertising Celebrex in magazines in 2006, and resumed television advertising in April 2007 with an unorthodox, 2 1⁄2-minute advertisement which extensively discussed the adverse effects of Celebrex in comparison with other anti-inflammatory drugs. The ad drew criticism from the consumer advocacy group Public Citizen, which called the ad's comparisons misleading. Pfizer responded to Public Citizen's concerns with assurances that they are truthfully advertising the risk and benefits of Celebrex as set forth by the FDA.
In late 2007, Pfizer released another US television ad for Celebrex, which also discussed celecoxib's adverse effects in comparison with those of other anti-inflammatory drugs.
Society and culture
A month supply in the United Kingdom costs the NHS less than £2 as of 2019. In the United States, the wholesale cost of this amount is about $US12.90. In 2011, it was one of Pfizer's best-selling medications, with $2.5 billion in sales. In 2017, it was the 106th most commonly prescribed medication in the United States, with more than seven million prescriptions.
Pfizer markets celecoxib under the brand name Celebrex, and it is available as oral capsules containing 50, 100, 200 or 400 mg of celecoxib.
It is legally available in many jurisdictions as a generic under several brand names. In the US, celecoxib was covered by three patents, two of which expired on May 30, 2014, and one of which (US RE44048) was due to expire December 2, 2015. On March 13, 2014, that patent was found to be invalid for double patenting. Upon the patent expiry on May 30, 2014, the FDA approved the first versions of generic celecoxib.
Fabricated efficacy studies
Pfizer and its partner, Pharmacia presented findings from their study that Celebrex was "better in protecting the stomach from serious complications than other drugs." This became Celebrex's main selling point. However, following federal investigations it was revealed that Pfizer and Pharmacia "only presented the results from the first six months of a year long study rather than the whole thing." These partial results were then published in The Journal of the American Medical Association. In 2001, the US Food and Drug Administration (FDA) released the full results of the Pfizer and Pharmacia study which showed that they had withheld crucial data. By 2012, a federal judge unsealed "thousands of pages of internal documents and depositions" in a "long-running securities fraud case against Pfizer."
On March 11, 2009, Scott S. Reuben, former chief of acute pain at Baystate Medical Center, Springfield, Massachusetts, revealed that the data for 21 studies he had authored for the efficacy of the drug (along with others such as Vioxx) had been fabricated. The analgesic effects of the drugs had been exaggerated. Reuben was also a former paid spokesperson for Pfizer. Although from 2002 to 2007 Pfizer underwrote much of Dr. Reuben's research and "many of his trials found that Celebrex and Lyrica, Pfizer drugs, were effective against postoperative pain," Pfizer was not aware of the fraudulent data.[failed verification] None of the retracted studies were submitted to either the US Food and Drug Administration or the European Union's regulatory agencies prior to the drug's approval. Although Pfizer issued a public statement declaring, "It is very disappointing to learn about Dr. Scott Reuben's alleged actions. When we decided to support Dr. Reuben's research, he worked for a credible academic medical center and appeared to be a reputable investigator", the documents unsealed in 2012, revealed that by February 2000, Pharmacia employees had devised a strategy to present the findings.
The role celecoxib might have in reducing the rates of certain cancers has been the subject of many studies. However, no medical recommendation exists to use this drug for cancer reduction.[when?][medical citation needed]
The use of celecoxib to reduce the risk of colorectal cancer has been investigated, but neither celecoxib nor any other drug is indicated for this use. Small-scale clinical trials in very high-risk people (belonging to FAP families) showed celecoxib can prevent polyp growth. Hence, large-scale randomized clinical trials were undertaken. Results show a 33 to 45% polyp recurrence reduction in people treated with celecoxib each day. However, serious cardiovascular events were significantly more frequent in the celecoxib-treated groups. Aspirin shows a similar (and possibly larger) protective effect, has demonstrated cardioprotective effects and is significantly cheaper, but no head-to-head clinical trials have compared the two drugs.
Different from cancer prevention, cancer treatment is focused on the therapy of tumors that have already formed and have established themselves inside the patient. Many studies are going on to determine whether celecoxib might be useful for this latter condition. However, during molecular studies in the laboratory, it became apparent that celecoxib could interact with other intracellular components besides its most famous target, COX-2. The discovery of these additional targets has generated much controversy, and the initial assumption that celecoxib reduces tumor growth primarily by the inhibition of COX-2 became contentious.
Certainly, the inhibition of COX-2 is paramount for the anti-inflammatory and analgesic function of celecoxib. However, whether inhibition of COX-2 also plays a dominant role in this drug's anticancer effects is unclear. For example, a recent study with malignant tumor cells showed celecoxib could inhibit the growth of these cells in vitro, but COX-2 played no role in this outcome; even more strikingly, the anticancer effects of celecoxib were also obtained with the use of cancer cell types that do not even contain COX-2.
Additional support for the idea that other targets besides COX-2 are important for celecoxib's anticancer effects has come from studies with chemically modified versions of celecoxib. Several dozen analogs of celecoxib were generated with small alterations in their chemical structures. Some of these analogs retained COX-2 inhibitory activity, whereas many others did not. However, when the ability of all these compounds to kill tumor cells in cell culture was investigated, the antitumor potency did not at all depend on whether or not the respective compound could inhibit COX-2, showing the inhibition of COX-2 was not required for the anticancer effects. One of these compounds, 2,5-dimethyl-celecoxib, which entirely lacks the ability to inhibit COX-2, actually displayed stronger anticancer activity than celecoxib.
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 "Celecoxib Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. 11 November 2019. Archived from the original on 20 May 2019. Retrieved 5 May 2020.
- ↑ 2.0 2.1 2.2 2.3 2.4 "Celecoxib (Celebrex) Use During Pregnancy". Drugs.com. 4 May 2020. Archived from the original on 25 January 2021. Retrieved 5 May 2020.
- ↑ 3.0 3.1 "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 2 July 2020. Retrieved 9 September 2020.
- ↑ "Celebrex 100mg capsule - Summary of Product Characteristics (SmPC)". (emc). 13 January 2020. Archived from the original on 6 August 2020. Retrieved 5 May 2020.
- ↑ 5.0 5.1 5.2 5.3 5.4 McCormack PL (December 2011). "Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis". Drugs. 71 (18): 2457–89. doi:10.2165/11208240-000000000-00000. PMID 22141388.
- ↑ 6.0 6.1 6.2 6.3 Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanas A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C (August 2013). "Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials". Lancet. 382 (9894): 769–79. doi:10.1016/S0140-6736(13)60900-9. PMC 3778977. PMID 23726390.
- ↑ 7.0 7.1 7.2 Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA (March 2007). "Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association". Circulation. 115 (12): 1634–42. doi:10.1161/circulationaha.106.181424. PMID 17325246.
- ↑ "Should you still take Celebrex?". Consumer Reports. August 2009. Archived from the original on 18 December 2015. Retrieved 27 December 2015.
- ↑ 9.0 9.1 Stein, Rob (25 April 2018). "FDA Panel Affirms Safety Of Painkiller Celebrex". NPR. Archived from the original on 20 May 2018. Retrieved 19 May 2018.
- ↑ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 522. ISBN 9783527607495. Archived from the original on 28 August 2021. Retrieved 30 April 2020.
- ↑ 11.0 11.1 11.2 British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 1097–1098. ISBN 9780857113382.
- ↑ 12.0 12.1 "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
- ↑ 13.0 13.1 13.2 13.3 13.4 13.5 13.6 13.7 13.8 Thomas, Katie (24 June 2012). "In Documents on Pain Drug, Signs of Doubt and Deception". The New York Times. Archived from the original on 3 January 2016. Retrieved 27 December 2015.
- ↑ 14.0 14.1 "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
- ↑ 15.0 15.1 "Celecoxib - Drug Usage Statistics". ClinCalc. Archived from the original on 12 April 2020. Retrieved 11 April 2020.
- ↑ Derry S, Moore RA (October 2013). "Single dose oral celecoxib for acute postoperative pain in adults". The Cochrane Database of Systematic Reviews. 10 (10): CD004233. doi:10.1002/14651858.CD004233.pub4. PMC 4161494. PMID 24150982.
- ↑ Yelland MJ, Nikles CJ, McNairn N, Del Mar CB, Schluter PJ, Brown RM (January 2007). "Celecoxib compared with sustained-release paracetamol for osteoarthritis: a series of n-of-1 trials". Rheumatology. 46 (1): 135–40. doi:10.1093/rheumatology/kel195. PMID 16777855.
- ↑ Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P (September 2007). "OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence". Osteoarthritis and Cartilage. 15 (9): 981–1000. doi:10.1016/j.joca.2007.06.014. PMID 17719803.
- ↑ Flood J (March 2010). "The role of acetaminophen in the treatment of osteoarthritis". The American Journal of Managed Care. 16 Suppl Management: S48–54. PMID 20297877.
- ↑ Puljak L, Marin A, Vrdoljak D, Markotic F, Utrobicic A, Tugwell P (May 2017). "Celecoxib for osteoarthritis". The Cochrane Database of Systematic Reviews. 5: CD009865. doi:10.1002/14651858.CD009865.pub2. PMC 6481745. PMID 28530031.
- ↑ Müller N, Myint AM, Krause D, Weidinger E, Schwarz MJ (April 2013). "Anti-inflammatory treatment in schizophrenia". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 42: 146–53. doi:10.1016/j.pnpbp.2012.11.008. PMID 23178230.
- ↑ Na KS, Lee KJ, Lee JS, Cho YS, Jung HY (January 2014). "Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 48: 79–85. doi:10.1016/j.pnpbp.2013.09.006. PMID 24056287.
- ↑ Rosenblat JD, Cha DS, Mansur RB, McIntyre RS (August 2014). "Inflamed moods: a review of the interactions between inflammation and mood disorders". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 53: 23–34. doi:10.1016/j.pnpbp.2014.01.013. PMID 24468642.
- ↑ Fond G, Hamdani N, Kapczinski F, Boukouaci W, Drancourt N, Dargel A, Oliveira J, Le Guen E, Marlinge E, Tamouza R, Leboyer M (March 2014). "Effectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review". Acta Psychiatrica Scandinavica. 129 (3): 163–79. doi:10.1111/acps.12211. PMID 24215721.
- ↑ Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M (March 2005). "Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention". The New England Journal of Medicine. 352 (11): 1071–80. doi:10.1056/NEJMoa050405. PMID 15713944.
- ↑ 26.0 26.1 26.2 26.3 26.4 26.5 26.6 26.7 26.8 "Celebrex- celecoxib capsule". DailyMed. 31 May 2019. Archived from the original on 24 February 2021. Retrieved 5 May 2020.
- ↑ 27.0 27.1 "FDA Warns that Using a Type of Pain and Fever Medication in Second Half of Pregnancy Could Lead to Complications". U.S. Food and Drug Administration (FDA) (Press release). 15 October 2020. Archived from the original on 16 October 2020. Retrieved 15 October 2020. This article incorporates text from this source, which is in the public domain.
- ↑ 28.0 28.1 "NSAIDs may cause rare kidney problems in unborn babies". U.S. Food and Drug Administration. 21 July 2017. Archived from the original on 17 October 2020. Retrieved 15 October 2020. This article incorporates text from this source, which is in the public domain.
- ↑ Nissen SE, Yeomans ND, Solomon DH, Lüscher TF, Libby P, Husni ME, Graham DY, Borer JS, Wisniewski LM, Wolski KE, Wang Q, Menon V, Ruschitzka F, Gaffney M, Beckerman B, Berger MF, Bao W, Lincoff AM (December 2016). "Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis". The New England Journal of Medicine. 375 (26): 2519–29. doi:10.1056/NEJMoa1611593. PMID 27959716.
- ↑ Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL (February 2005). "Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction". Annals of Internal Medicine. 142 (3): 157–64. doi:10.7326/0003-4819-142-3-200502010-00005. PMID 15684203.
- ↑ Mukherjee D, Nissen SE, Topol EJ (2001). "Risk of cardiovascular events associated with selective COX-2 inhibitors". JAMA. 286 (8): 954–9. doi:10.1001/jama.286.8.954. PMID 11509060.
- ↑ Jenkins JK, Seligman PJ (6 April 2005). "Analysis and recommendations for Agency action regarding nonsteroidal anti-inflammatory drugs and cardiovascular risk [decision memorandum]" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original (PDF) on 9 September 2005.
- ↑ Chen LC, Ashcroft DM (December 2006). "Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials". Journal of Clinical Pharmacy and Therapeutics. 31 (6): 565–76. doi:10.1111/j.1365-2710.2006.00774.x. PMID 17176361.
- ↑ Turner, M. S.; May, D. B.; Arthur, R. R.; Xiong, G. L. (2007). "Clinical impact of selective serotonin reuptake inhibitors therapy with bleeding risks". Journal of Internal Medicine. 261 (3): 205–213. doi:10.1111/j.1365-2796.2006.01720.x. ISSN 1365-2796. PMID 17305643.
- ↑ 35.0 35.1 Mathew ST, Devi SG, Prasanth VV, Vinod B (2011). "Efficacy and Safety of COX-2 Inhibitors in the Clinical Management of Arthritis: Mini Review". ISRN Pharmacology. 2011: 480291. doi:10.5402/2011/480291. PMC 3197256. PMID 22084715.
- ↑ 36.0 36.1 Katzung, Bertram G. (2007). Basic & clinical pharmacology (10th ed.). New York: McGraw-Hill Medical. p. 579. ISBN 9780071451536.
- ↑ Shi S, Klotz U (March 2008). "Clinical use and pharmacological properties of selective COX-2 inhibitors". European Journal of Clinical Pharmacology. 64 (3): 233–52. doi:10.1007/s00228-007-0400-7. PMID 17999057.
- ↑ Conaghan PG (June 2012). "A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity". Rheumatology International. 32 (6): 1491–502. doi:10.1007/s00296-011-2263-6. PMC 3364420. PMID 22193214.
- ↑ DiPiro, Joseph T., Robert L. Talbert, Gary C. Yee, Gary R. Matzke, Barbara G. Wells, and L. Michael Posey. Pharmacotherapy A Pathophysiologic Approach (Pharmacotherapy (Dipiro) Pharmacotherapy (Dipiro)). New York: McGraw-Hill Medical, 2008. Print.
- ↑ Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM, Harrington RA, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Hlatky MA, Kaul S, Lindner JR, Moliterno DJ, Mukherjee D, Schofield RS, Rosenson RS, Stein JH, Weitz HH, Wesley DJ (October 2008). "ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents". Journal of the American College of Cardiology. 52 (18): 1502–17. doi:10.1016/j.jacc.2008.08.002. PMID 19017521.
- ↑ Half E, Arber N (February 2009). "Colon cancer: preventive agents and the present status of chemoprevention". Expert Opinion on Pharmacotherapy. 10 (2): 211–9. doi:10.1517/14656560802560153. PMID 19236194.
- ↑ 42.0 42.1 42.2 Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY, Isakson PC (April 1997). "Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib)". Journal of Medicinal Chemistry. 40 (9): 1347–65. doi:10.1021/jm960803q. PMID 9135032.
- ↑ 43.0 43.1 Price ML, Jorgensen WL (June 2001). "Rationale for the observed COX-2/COX-1 selectivity of celecoxib from Monte Carlo simulations". Bioorganic & Medicinal Chemistry Letters. 11 (12): 1541–4. doi:10.1016/s0960-894x(00)00522-9. PMID 11412976.
- ↑ Langreth, Robert (23 June 2003). "The Chemical Cobbler". Forbes. Archived from the original on 16 April 2018. Retrieved 15 April 2018.
- ↑ "Dr. John Talley: 2001 St. Louis Awardee" (PDF). Chemical Bond. 52 (5): 2. May 2001. Archived from the original (PDF) on 15 April 2018.
- ↑ Yajnik J (27 October 2006). "University sues Pfizer over COX-2 research". The Scientist. Archived from the original on 3 February 2009. Retrieved 11 November 2010.
- ↑ Linda Thomson (28 October 2009). "Judge orders Pfizer to pay BYU $852K for suit delays". Deseret News. Archived from the original on 31 October 2009. Retrieved 23 November 2009.
- ↑ Harvey, Tom (1 May 2012). "Pfizer, BYU settle Celebrex lawsuit for $450M". The Salt Lake Tribune. Archived from the original on 3 March 2016. Retrieved 22 July 2012.
- ↑ "Pfizer Settles B.Y.U. Lawsuit Over Development of Celebrex". The New York Times. Associated Press. 1 May 2012. Archived from the original on 27 December 2017. Retrieved 5 May 2020.
- ↑ U.S. Patent 6,048,850
- ↑ 51.0 51.1 "Reach-Through Claims Declared Invalid". Archived from the original on 22 February 2014. Retrieved 31 December 2012.
- ↑ 52.0 52.1 Ranjana Kadle (2004) CAFC Court Decision Reach-Through Claims Declared Invalid
- ↑ 53.0 53.1 53.2 "Philip Needleman". National Academy of Sciences. 15 June 2015. Archived from the original on 7 January 2016. Retrieved 28 December 2015.
- ↑ U.S. Patent 5,466,823
- ↑ "Drug Approval Package: Celebrex (Celecoxib) NDA# 20-998". U.S. Food and Drug Administration (FDA). 24 December 1999. Archived from the original on 27 March 2019. Retrieved 5 May 2020.
- ↑ Berenson A (29 April 2006). "Celebrex Ads Are Back, Dire Warnings and All". The New York Times. Archived from the original on 7 January 2016. Retrieved 21 February 2017.
- ↑ 57.0 57.1 Saul S (10 April 2007). "Celebrex Commercial, Long and Unconventional, Draws Criticism". The New York Times. Archived from the original on 17 January 2018. Retrieved 21 February 2017.
- ↑ "Celecoxib". Drugs.com. 4 May 2020. Archived from the original on 10 March 2016. Retrieved 5 May 2020.
- ↑ "US Re-issued Patent RE44048". Archived from the original on 9 January 2017. Retrieved 10 November 2016.
- ↑ Parloff, Roger (13 March 2014). "Judge cuts 18 months off patent life of Pfizer's Celebrex". Fortune. Archived from the original on 25 July 2017. Retrieved 5 May 2020.
- ↑ "FDA approves first generic versions of celecoxib". U.S. Food and Drug Administration (FDA) (Press release). 31 May 2014. Archived from the original on 31 May 2014. Retrieved 5 May 2020.
- ↑ Harris, Gardiner (11 March 2009). "Doctor Admits Pain Studies Were Frauds, Hospital Says". The New York Times. Archived from the original on 17 May 2017. Retrieved 27 December 2015.
- ↑ Winstein, Keith J. (11 March 2009). "Top Pain Scientist Fabricated Data in Studies, Hospital Says". The Wall Street Journal. Archived from the original on 30 August 2017. Retrieved 3 August 2017.
- ↑ "Associated Press, Mar 11, 2009, Mass. doctor accused of faking pain pill data". Archived from the original on 16 March 2009.
- ↑ Rial NS, Zell JA, Cohen AM, Gerner EW (August 2012). "Clinical end points for developing pharmaceuticals to manage patients with a sporadic or genetic risk of colorectal cancer". Expert Review of Gastroenterology & Hepatology. 6 (4): 507–17. doi:10.1586/egh.12.23. PMC 3587976. PMID 22928902.
- ↑ Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET (August 2006). "Celecoxib for the prevention of sporadic colorectal adenomas". The New England Journal of Medicine. 355 (9): 873–84. doi:10.1056/NEJMoa061355. PMID 16943400.
- ↑ Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F, van Stolk RU (March 2003). "A randomized trial of aspirin to prevent colorectal adenomas". The New England Journal of Medicine. 348 (10): 891–9. doi:10.1056/NEJMoa021735. PMID 12621133.
- ↑ Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R (March 2003). "A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer". The New England Journal of Medicine. 348 (10): 883–90. doi:10.1056/NEJMoa021633. PMID 12621132.
- ↑ Bosetti C, Talamini R, Franceschi S, Negri E, Garavello W, La Vecchia C (March 2003). "Aspirin use and cancers of the upper aerodigestive tract". British Journal of Cancer. 88 (5): 672–4. doi:10.1038/sj.bjc.6600820. PMC 2376339. PMID 12618872.
- ↑ Dannenberg AJ, Subbaramaiah K (December 2003). "Targeting cyclooxygenase-2 in human neoplasia: rationale and promise". Cancer Cell. 4 (6): 431–6. doi:10.1016/S1535-6108(03)00310-6. PMID 14706335.
- ↑ Schönthal AH (December 2007). "Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy". British Journal of Cancer. 97 (11): 1465–8. doi:10.1038/sj.bjc.6604049. PMC 2360267. PMID 17955049.
- ↑ Chuang HC, Kardosh A, Gaffney KJ, Petasis NA, Schönthal AH (May 2008). "COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro". Molecular Cancer. 7 (1): 38. doi:10.1186/1476-4598-7-38. PMC 2396175. PMID 18485224.
- ↑ 73.0 73.1 Zhu J, Song X, Lin HP, Young DC, Yan S, Marquez VE, Chen CS (December 2002). "Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents" (PDF). Journal of the National Cancer Institute. 94 (23): 1745–57. doi:10.1093/jnci/94.23.1745. PMID 12464646. Archived (PDF) from the original on 7 January 2016. Retrieved 25 June 2012.
- ↑ Schönthal AH, Chen TC, Hofman FM, Louie SG, Petasis NA (February 2008). "Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs". Expert Opinion on Investigational Drugs. 17 (2): 197–208. doi:10.1517/135437126.96.36.199. PMID 18230053.
- ↑ Schönthal AH (April 2006). "Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy". Neurosurgical Focus. 20 (4): E21. doi:10.3171/foc.2006.20.4.14. PMID 16709027.
- Dean L (2016). "Celecoxib Therapy and CYP2C9 Genotype". In Pratt VM, McLeod HL, Rubinstein WS, et al. (eds.). Medical Genetics Summaries. National Center for Biotechnology Information (NCBI). PMID 28520369. Bookshelf ID: NBK379478. Archived from the original on 26 October 2020. Retrieved 7 February 2020.
- Zhang J, Ding EL, Song Y (October 2006). "Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials". JAMA. 296 (13): 1619–32. doi:10.1001/jama.296.13.jrv60015. PMID 16968832.
- "COX-2 Selective (includes Bextra, Celebrex, and Vioxx) and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)". U.S. Food and Drug Administration (FDA). 15 July 2005. Archived from the original on 6 May 2020. Retrieved 6 May 2020.
- "FDA Approves Labeling Supplement for Celebrex (celecoxib)". U.S. Food and Drug Administration (FDA). 28 June 2018. Archived from the original on 6 May 2020. Retrieved 6 May 2020.
- Pages using duplicate arguments in template calls
- CS1: long volume value
- Use dmy dates from February 2020
- Articles with invalid date parameter in template
- Drugs with non-standard legal status
- Chem-molar-mass both hardcoded and calculated
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugs missing an ATC code
- Drugboxes which contain changes to watched fields
- All articles with unsourced statements
- Articles with unsourced statements from December 2019
- Articles with hatnote templates targeting a nonexistent page
- All articles with failed verification
- Articles with failed verification from August 2018
- All articles with vague or ambiguous time
- Vague or ambiguous time from May 2020
- Articles with unsourced statements from May 2020
- Antineoplastic drugs
- COX-2 inhibitors
- Nonsteroidal anti-inflammatory drugs
- Pfizer brands
- Trifluoromethyl compounds